Solid-phase N-terminus PEGylation of recombinant human fibroblast growth factor 2 on heparin-sepharose column

Bioconjugate Chemistry

Volumn 23, Issue 4, 2012, Pages 740-750

  Huang, Zhifeng ^a,b   Ye, Chaohui ^a   Liu, Zhijun ^c   Wang, Xiaojie ^a   Chen, Huaibin ^a   Liu, Yanlong ^a   Tang, Lu ^a   Zhao, Hongxin ^c   Wang, Junfeng ^c   Feng, Wenke ^a,d   Li, Xiaokun ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b Basic Medical College   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; CELL CULTURE; CELL PROLIFERATION; FIBROBLASTS; MASS SPECTROMETRY; POLYETHYLENE GLYCOLS; PROTEINS; TISSUE REGENERATION;

CLINICAL APPLICATION; FIBROBLAST GROWTH FACTOR-2; HUMAN FIBROBLAST; N TERMINUS; PEGYLATED; PEGYLATED PROTEINS; PEGYLATION; SOLID PHASIS; SOLID-PHASE; SOLUTION PHASE;

POLYSACCHARIDES;

BUTYRALDEHYDE; FIBROBLAST GROWTH FACTOR 2; HEPARIN; MACROGOL; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; SEPHAROSE; UNCLASSIFIED DRUG;

ALKYLATION; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PURITY; IMMUNOGENICITY; IN VITRO STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PROTEIN SECONDARY STRUCTURE; RAT; REACTION TIME; RECEPTOR BINDING; SOLID; THERMOSTABILITY;

EID: 84859966057     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200550f     Document Type: Article

References (50)

1. Baird, A., and Klagsbrun, M. (1991) The fibroblast growth factor family. Cancer Cells 3, 239-43.
2. McKeehan, W. L., Wang, F., and Kan, M. (1998) The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog. Nucleic Acid Res. Mol. Biol. 59, 135-76.
3. Marks, M. G., Doillon, C., and Silver, F. H. (1991) Effects of fibroblasts and basic fibroblast growth factor on facilitation of dermal wound healing by type I collagen matrices. J. Biomed. Mater. Res. 25, 683-96.
4. Raimondi, A. R., Molinolo, A. A., and Itoiz, M. E. (2006) Fibroblast growth factor-2 expression during experimental oral carcinogenesis. Its possible role in the induction of pre-malignant fibrosis. J. Oral Pathol. Med. 35, 212-7. (Pubitemid 43362952)
5. Gerwins, P., Skoldenberg, E., and Claesson-Welsh, L. (2000) Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis. Crit. Rev. Oncol. Hematol. 34, 185-94. (Pubitemid 30320963)
6. Kurane, A., Simionescu, D. T., and Vyavahare, N. R. (2007) In vivo cellular repopulation of tubular elastin scaffolds mediated by basic fibroblast growth factor. Biomaterials 28, 2830-8. (Pubitemid 46482660)
7. Jiang, X., Zou, S., Ye, B., Zhu, S., Liu, Y., and Hu, J. (2010) bFGFModified BMMSCs enhance bone regeneration following distraction osteogenesis in rabbits. Bone 46, 1156-61.
8. Rabchevsky, A. G., Fugaccia, I., Turner, A. F., Blades, D. A., Mattson, M. P., and Scheff, S. W. (2000) Basic fibroblast growth factor (bFGF) enhances functional recovery following severe spinal cord injury to the rat. Exp. Neurol. 164, 280-91. (Pubitemid 32008973)
9. Bogousslavsky, J., Victor, S. J., Salinas, E. O., Pallay, A., Donnan, G. A., Fieschi, C., Kaste, M., Orgogozo, J. M., Chamorro, A., and Desmet, A. (2002) Fiblast (trafermin) in acute stroke: results of the European-Australian phase II/III safety and efficacy trial. Cerebrovasc. Dis. 14, 239-51. (Pubitemid 36151425)
10. Kawaguchi, H., Nakamura, K., Tabata, Y., Ikada, Y., Aoyama, I., Anzai, J., Nakamura, T., Hiyama, Y., and Tamura, M. (2001) Acceleration of fracture healing in nonhuman primates by fibroblast growth factor-2. J. Clin. Endocrinol. Metab. 86, 875-80. (Pubitemid 32207509)
11. Katre, N. V. (1990) Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol. 144, 209-13.
12. Bory, C., Boulieu, R., Souillet, G., Chantin, C., Guibaud, P., and Hershfield, M. S. (1991) Effect of polyethylene glycol-modified adenosine deaminase (PEG-ADA) therapy in two ADA-deficient children: measurement of erythrocyte deoxyadenosine triphosphate as a useful tool. Adv. Exp. Med. Biol. 309A, 173-6.
13. DeSantis, G., and Jones, J. B. (1999) Chemical modification of enzymes for enhanced functionality. Curr. Opin. Biotechnol. 10, 324-30. (Pubitemid 29373944)
14. Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M. H., and Albrecht, J. (2002) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122, 1303-13. (Pubitemid 34465173)
15. Veronese, F. M., and Pasut, G. (2005) PEGylation, successful approach to drug delivery. Drug Discovery Today 10, 1451-8. (Pubitemid 41483874)
16. Caliceti, P., and Veronese, F. M. (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Delivery Rev. 55, 1261-77. (Pubitemid 37464561)
17. George, S., Hutson, T. E., Mekhail, T., Wood, L., Finke, J., Elson, P., Dreicer, R., and Bukowski, R. M. (2008) Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma. Cancer Chemother. Pharmacol. 62, 347-54. (Pubitemid 351692077)
18. Tamai, H., Shingaki, N., Shiraki, T., Tukuda, H., Mori, Y., Moribata, K., Enomoto, S., Deguchi, H., Ueda, K., Inoue, I., Maekita, T., Iguchi, M., Yanaoka, K., Oka, M., and Ichinose, M. (2011) Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation. Hepatol. Res.,
19. Hu, J., Duppatla, V., Harth, S., Schmitz, W., and Sebald, W. (2010) Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues. Bioconjugate Chem. 21, 1762-72.
20. Filpula, D., Yang, K., Basu, A., Hassan, R., Xiang, L., Zhang, Z., Wang, M., Wang, Q. C., Ho, M., Beers, R., Zhao, H., Peng, P., Zhou, J., Li, X., Petti, G., Janjua, A., Liu, J., Wu, D., Yu, D., Longley, C., FitzGerald, D., Kreitman, R. J., and Pastan, I. (2007) Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconjugate Chem. 18, 773-84. (Pubitemid 47010797)
21. Lee, H., Jang, I. H., Ryu, S. H., and Park, T. G. (2003) Nterminal site-specific mono-PEGylation of epidermal growth factor. Pharm. Res. 20, 818-25. (Pubitemid 36515317)
22. Fee, C. J., and Alstine, J. M. V. (2006) PEG-protein:reaction engineering and separation issues. Chem. Eng. Sci. 61, 924-939.
23. Basu, A., Yang, K., Wang, M., Liu, S., Chintala, R., Palm, T., Zhao, H., Peng, P., Wu, D., Zhang, Z., Hua, J., Hsieh, M. C., Zhou, J., Petti, G., Li, X., Janjua, A., Mendez, M., Liu, J., Longley, C., Mehlig, M., Borowski, V., Viswanathan, M., and Filpula, D. (2006) Structurefunction engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjugate Chem. 17, 618-30. (Pubitemid 43794371)
24. Marsac, Y., Cramer, J., Olschewski, D., Alexandrov, K., and Becker, C. F. (2006) Site-specific attachment of polyethylene glycollike oligomers to proteins and peptides. Bioconjugate Chem. 17, 1492-8. (Pubitemid 44851494)
25. Xiao, J., Burn, A., and Tolbert, T. J. (2008) Increasing solubility of proteins and peptides by site-specific modification with betaine. Bioconjugate Chem. 19, 1113-8. (Pubitemid 351874930)
26. Dou, H., Zhang, M., Zhang, Y., and Yin, C. (2007) Synthesis and purification of mono-PEGylated insulin. Chem. Biol. Drug Des. 69, 132-8. (Pubitemid 46457520)
27. Lee, B. K., Kwon, J. S., Kim, H. J., Yamamoto, S., and Lee, E. K. (2007) Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity. Bioconjugate Chem. 18, 1728-34. (Pubitemid 350219969)
28. Suo, X., Lu, X., Hu, T., Ma, G., and Su, Z. (2009) A solid-phase adsorption method for PEGylation of human serum albumin and staphylokinase: preparation, purification and biochemical characterization. Biotechnol. Lett. 31, 1191-6.
29. Wu, Z. L., Zhang, L., Yabe, T., Kuberan, B., Beeler, D. L., Love, A., and Rosenberg, R. D. (2003) The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex. J. Biol. Chem. 278, 17121-9. (Pubitemid 36799590)
30. Berman, B., Ostrovsky, O., Shlissel, M., Lang, T., Regan, D., Vlodavsky, I., Ishai-Michaeli, R., and Ron, D. (1999) Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor. J. Biol. Chem. 274, 36132-8.
31. Spielberger, R., Stiff, P., Bensinger, W., Gentile, T., Weisdorf, D., Kewalramani, T., Shea, T., Yanovich, S., Hansen, K., Noga, S., McCarty, J., LeMaistre, C. F., Sung, E. C., Blazar, B. R., Elhardt, D., Chen, M. G., and Emmanouilides, C. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 351, 2590-8. (Pubitemid 39628580)
32. Seeger, A., and Rinas, U. (1996) Two-step chromatographic procedure for purification of basic fibroblast growth factor from recombinant Escherichia coli and characterization of the equilibrium parameters of adsorption. J. Chromatogr., A 746, 17-24. (Pubitemid 26343007)
33. Anspach, F. B., Spille, H., and Rinas, U. (1995) Purification of recombinant human basic fibroblast growth factor: stability of selective sorbents under cleaning in place conditions. J. Chromatogr., A 711, 129-39.
34. Balan, S., Choi, J. W., Godwin, A., Teo, I., Laborde, C. M., Heidelberger, S., Zloh, M., Shaunak, S., and Brocchini, S. (2007) Sitespecific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconjugate Chem. 18, 61-76. (Pubitemid 46145995)
35. Niall, H. D. (1973) Automated Edman degradation: the protein sequenator. Methods Enzymol. 27, 942-1010.
36. Wu, X., Yan, Q., Huang, Y., Huang, H., Su, Z., Xiao, J., Zeng, Y., Wang, Y., Nie, C., Yang, Y., and Li, X. (2010) Isolation of a novel basic FGF-binding peptide with potent antiangiogenetic activity. J. Cell Mol. Med. 14, 351-6.
37. Huang, Z., Ni, C., Chu, Y., Wang, S., Yang, S., Wu, X., Wang, X., Li, X., Feng, W., and Lin, S. (2009) Chemical modification of recombinant human keratinocyte growth factor 2 with polyethylene glycol improves biostability and reduces animal immunogenicity. J. Biotechnol. 142, 242-9.
38. Schlessinger, J., Plotnikov, A. N., Ibrahimi, O. A., Eliseenkova, A. V., Yeh, B. K., Yayon, A., Linhardt, R. J., and Mohammadi, M. (2000) Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 6, 743-50.
39. Zalipsky, S. (1995) Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv. Drug Delivery Rev. 16, 157-182.
40. Conover, C. D., Greenwald, R. B., Pendri, A., and Shum, K. L. (1999) Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs. Anti-Cancer Drug Des. 14, 499-506. (Pubitemid 30258969)
41. Cai, Y., and Yue, P. (2011) Separation of exenatide analogue mono-PEGylated with 40 kDA polyethylene glycol by cation exchange chromatography. J. Chromatogr., A 1218, 6953-60.
42. Zern, B. J., Chu, H., and Wang, Y. (2010) Control growth factor release using a self-assembled [polycation:heparin] complex. PLoS One 5, e11017.
43. Chu, H., Johnson, N. R., Mason, N. S., and Wang, Y. (2011) A [polycation:heparin] complex releases growth factors with enhanced bioactivity. J. Controlled Release 150, 157-63.
44. Huang, Z., Wang, H., Lu, M., Sun, C., Wu, X., Tan, Y., Ye, C., Zhu, G., Wang, X., Cai, L., and Li, X. (2011) A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS One 6, e20669.
45. Kubetzko, S., Sarkar, C. A., and Pluckthun, A. (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol. Pharmacol. 68, 1439-54. (Pubitemid 41540000)
46. Dhalluin, C., Ross, A., Huber, W., Gerber, P., Brugger, D., Gsell, B., and Senn, H. (2005) Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjugate Chem. 16, 518-27. (Pubitemid 40696042)
47. Yang, K., Basu, A., Wang, M., Chintala, R., Hsieh, M. C., Liu, S., Hua, J., Zhang, Z., Zhou, J., Li, M., Phyu, H., Petti, G., Mendez, M., Janjua, H., Peng, P., Longley, C., Borowski, V., Mehlig, M., and Filpula, D. (2003) Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. Protein Eng. 16, 761-70. (Pubitemid 37442447)
48. Scott, M. D., and Chen, A. M. (2004) Beyond the red cell: pegylation of other blood cells and tissues. Transfus. Clin. Biol. 11, 40-6. (Pubitemid 38230190)
49. Abe, K., and Saito, H. (2001) Effects of basic fibroblast growth factor on central nervous system functions. Pharmacol. Res. 43, 307-12. (Pubitemid 32607762)
50. Kuan, C. T., Wang, Q. C., and Pastan, I. (1994) Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. J. Biol. Chem. 269, 7610-6.